Disseminated Nocardiosis When Empiric Combination Therapy Has Not Achieved Improvement
This protocol addresses disseminated nocardiosis in patients who have undergone initial empiric combination antibiotic therapy but have not reached the expected clinical and radiographic milestones. It defines the structured next step when that first-line course is insufficient.
Previous Treatment — Goals Not Met
First-line management for disseminated nocardiosis typically centres on empiric combination therapy anchored by trimethoprim-sulfamethoxazole alongside additional agents. The anticipated endpoints — signs of clinical improvement and radiographic response on follow-up chest imaging — were not achieved, warranting escalation to this protocol.
Next-Line Approach (Partial Overview)
This protocol involves transitioning to an alternative antibiotic strategy guided by susceptibility results, together with consideration of adjusting immunosuppression where it can be done safely. The complete regimen selection, sequencing, and immunosuppression management guidance are in the full protocol.
References
DOI: 10.1093/cid/ciae643
- Patients with TMP-SMX toxicity and yet-to-improve severe infection may be better served transitioning to alternative therapy, as patients with severe nocardiosis are underrepresented in the available data.
- Linezolid is uniquely susceptible in vitro to essentially all Nocardia isolates.
- Reduction in immunosuppression is often performed for severe disease, though evidence supporting this is limited.
- Immunosuppression should be lowered or held if it can be done safely, recognizing the competing risks of rejection and graft-versus-host disease in transplant populations.
View source ↗